Bluebird bio details plans to file three blockbusters
Biotech looks to take on Novartis, Gilead, and Juno in CAR-T
X
Bluebird bio details plans to file three blockbusters
https://pharmaphorum.com/news/bluebird-bio-aims/
Juno
Cellectis gets FDA go-ahead to restart fatal CAR-T trial
Regulator agrees to restart phase 1 trial of UCART 123
Juno bounces back with ‘best in class’ CAR-T
Juno has hopes pinned on JCAR017
Juno boosted by CAR-T trial findings in NHL
Biotech plans pivotal trial next year.
Kite in CAR-T pole position as rolling submission begins
Kite to start filing data for KTE-C19 with US regulator.
Juno halts CAR-T trial again after 2 more deaths
Doubts over Juno CAR-T therapy after two more trial deaths.
Adaptimmune revives ovarian cancer trial
T-cell trial will include controversial chemo agent fludarabine.
Novartis committed to CAR-Ts – but doubts about commercial viability remain
Novartis may have concerns about commercial prospects, says expert.
1 2
